Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide

杜鲁特格拉维尔 替诺福韦-阿拉芬酰胺 医学 恩曲他滨 养生 内科学 阿巴卡韦 人口 人类免疫缺陷病毒(HIV) 埃替拉韦 病毒载量 抗逆转录病毒疗法 病毒学 环境卫生
作者
Ling-Ya Chen,Hsin‐Yun Sun,Yu‐Chung Chuang,Yu Huang,Wang-Da Liu,Kuan‐Yin Lin,Hsi-Yen Chang,Yi Luo,Pei‐Ying Wu,Yi‐Ching Su,Wen-Chun Liu,Chien‐Ching Hung
出处
期刊:Journal of Microbiology Immunology and Infection [Elsevier]
卷期号:56 (3): 575-585 被引量:5
标识
DOI:10.1016/j.jmii.2023.01.015
摘要

While some evidence has suggested the benefits of co-formulated bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) in improving the quality of life of people living with HIV (PLWH), patient-reported outcome studies that focus on Asian population remain scarce. We aimed to determine the changes in HIV-related symptom burden in virally-suppressed PLWH switching to B/F/TAF in a real-world setting. PLWH on stable antiretroviral therapy (ART) for ≥6 months with plasma HIV RNA <200 copies/mL who decided to switch to B/F/TAF were eligible for the study. Participants’ experience with 20 symptoms were assessed using HIV Symptom Index at baseline and weeks 24 and 48. Responses were dichotomized in two ways: 1) present vs. not present; and 2) bothersome vs. not bothersome, and compared across time points. Six hundred and thirty participants (prior regimen, 94.4% integrase inhibitor-based) who completed week 48 visit were included in the analysis. Forty-eight weeks after switching to B/F/TAF, six symptoms were significantly less prevalent, and seven symptoms were significantly less bothersome. Improvement was more pronounced in participants whose prior regimen was elvitegravir-based versus dolutegravir-based. Logistic regression results showed that prior dolutegravir-based ART and pre-existing diabetes independently predicted improvement in diarrhea/loose bowels and muscle aches/joint pain, respectively. Despite the overall improvement, some symptoms persisted in a substantial proportion of participants. Virally-suppressed PLWH might benefit from a regimen switch to B/F/TAF to reduce the prevalence and level of bother of HIV-related symptoms. Nevertheless, additional multidisciplinary interventions are warranted to further alleviate the symptom burden of PLWH.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
阳光凌青完成签到,获得积分10
刚刚
大漠孤烟完成签到,获得积分10
1秒前
2秒前
YB完成签到,获得积分10
2秒前
heyvan完成签到 ,获得积分10
2秒前
萧布完成签到,获得积分10
2秒前
666完成签到,获得积分10
2秒前
fan发布了新的文献求助10
2秒前
2秒前
重要羊发布了新的文献求助10
3秒前
idance完成签到,获得积分10
3秒前
心随以动发布了新的文献求助10
3秒前
Aokcers完成签到,获得积分20
3秒前
希望天下0贩的0应助TTTTTT采纳,获得10
3秒前
想飞的猪完成签到,获得积分10
4秒前
4秒前
Cameron完成签到,获得积分10
4秒前
文艺从彤完成签到,获得积分10
4秒前
小二郎应助幸福大白采纳,获得10
5秒前
辛勤的灵薇完成签到,获得积分10
5秒前
MOMO完成签到 ,获得积分10
5秒前
Aokcers发布了新的文献求助10
6秒前
齐嘉懿完成签到,获得积分10
6秒前
单薄茗完成签到,获得积分10
7秒前
尤珩发布了新的文献求助10
10秒前
JamesPei应助风中的丝袜采纳,获得30
10秒前
6000完成签到 ,获得积分10
10秒前
ppg123应助风中的丝袜采纳,获得30
10秒前
科研通AI2S应助风中的丝袜采纳,获得10
10秒前
搜集达人应助风中的丝袜采纳,获得10
10秒前
科研顺利完成签到,获得积分10
10秒前
小幸运完成签到,获得积分10
10秒前
努力向上的小刘完成签到,获得积分10
11秒前
yanghua完成签到 ,获得积分10
11秒前
励志梦完成签到,获得积分10
11秒前
11秒前
难过衬衫发布了新的文献求助10
11秒前
ZCY完成签到,获得积分10
12秒前
zhang完成签到 ,获得积分10
12秒前
Mr.Quinn完成签到,获得积分10
14秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Very-high-order BVD Schemes Using β-variable THINC Method 850
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3249053
求助须知:如何正确求助?哪些是违规求助? 2892387
关于积分的说明 8271490
捐赠科研通 2560723
什么是DOI,文献DOI怎么找? 1389228
科研通“疑难数据库(出版商)”最低求助积分说明 651029
邀请新用户注册赠送积分活动 627870